BIOGRAPHICAL SKETCH

Academic & Professional Background

• B.A. (Psychology) 1971 - University of Pennsylvania, Philadelphia
• M.D. 1975 - Hershey Medical Center, Penn State University, Philadelphia

Current Research Interests

• Atherogenesis
• Biomaterials
• Endothelial Cell Physiology
• Growth Factors
• Tissue Engineering
• Clinical Trials

Selected Publications

Xue L, Greisler HP. Biomaterials in the development and future of vascular grafts: A review. JVS (in press), 2002.

Erzurum V, Xue L, Burgess W. Greisler HP. The R136K fibroblast growth factor-1 mutant induces heparin-independent migration of endothelial cells but not smooth muscle cells through fibrin glue. JVS (in press), 2002.

Xue L, Greisler HP. Angiogenic effect of fibroblast growth factor-1 and vascular endothelial growth factor and their synergism in a novel in vitro quantitative fibrin-based three-dimensional angiogenesis system. Surgery 132(2):259-267, 2002.

Xue L, Tassiopoulos AK, Woloson S, Stanton Jr DL, Sullivan C, Hampton B, Burgess W, Greisler HP. Construction and biological characterization of an HB-GAM/FGF-1 chimera for vascular tissue engineering. JVS 33(3):554-560, 2001.

Xue L, Shireman P, Hampton B, Burgess W, Greisler HP. The sys-free fibroblast growth factor-1 mutant induces heparin-independent proliferation of endothelial cells and smooth muscle cells. J Surgical Research 92:255-260, 2000.

Shireman PK, Xue L, Szylobryt E, Burgess WH, Greisler HP. The S130K fibroblast growth factor-1 mutant S130K induces heparin-independent proliferation and is resistant to thrombin degradation in fibrin glue. J Vasc Surg 31:382-390, 2000.

Tassiopoulous A, Greisler HP. Angiogenic mechanisms for re-endothelialization of cardiovascular tissues and implants. J Biomaterial Science-Polymer Ed. 11(11):1275-1284, 2000.

Shireman PK, Greisler HP. Mitogenicity and release of vascular endothelial growth factor with and without heparin from fibrin glue. J of Vascular Surgery 31:936-943, 2000.

Shireman PK, Xue L, Maddox E, Burgess WH, Greisler HP. The S130K fibroblast growth factor-1 mutant induces heparin-independent proliferation and is resistant to thrombin degradation in fibrin glue. J of Vascular Surgery 31:382-390, 2000.

Xue L, Shireman PK, Hampton B, Burgess WH, Greisler HP. The cysteine-free fibroblast growth factor 1 mutant induces heparin-independent proliferation of endothelial cells and smooth muscle cells. J of Surgical Research 92:255-260, 2000.

Xue L, Greisler HP. Blood Vessels. Principles of Tissue Engineering 32:427-446, 2000.

Fox D, Kouris GJ, Blumofe KA, Heilizer TJ, Husak V, Greisler HP. Optimizing fluorescent labeling of endothelial cells for tracking during long-term studies of autologous transplantation. J of Surgical Research 86:9-16, 1999.

Mikucki SA, Greisler HP. Understanding and manipulating the biological response to vascular implants. Seminars in Vascular Surgery 12:18-26, 1999.

Greisler HP. Development of a Vascular Supply in vitro. In: Human In Vitro Organogenesis. Johnson PC (Ed.), CRC Press, Boca Raton, FL, (In press), 1998.

Zarge JI, Gosselin C, Huang P, Greisler HP. Platelet deposition on ePTFE grafts coated with fibrin glue with or without FGF-1 and heparin. J Surg Res 67:4-8, 1997.

Greisler HP. Macrophages. In: Basic Science of Vascular Disease, 2nd Edition. Sidawy AN, Sumpio BE, Giordano JM, DePalma RG (Eds.), pp 227-244, 1997.

Zarge JI, Huang P, Husak V, Kim DU, Haudenschild CC, Greisler HP. Fibrin glue containgin FGF-1 and heparin with autogogous EC reduces intimal hyperplasia in a canine carotid artery balloon injury model. J Vasc Surg (in press), 1997.

Greisler HP. Regulation of vascular graft healing by induction of tissue incorporation. In: Human Biomaterials Applications. Wise DL , Trantolo DJ, Altobelli DE, Yaszemski MJ, Gresser JD (Eds.), Humana Press, Inc., pp 393-413, 1996.

Gosselin C, Vorp DA, Warty V, Severyn DA, Dick EK, Borovetz HS, Greisler HP. ePTFE coating with fibrin glue, FGF-1 and heparin: Effect on retention of seeded endothelial cells. J Surg Res 60:327-332, 1996.

Hirko MK, Lin PH, Gosselin C, Ren D, Greisler HP. In vivo tissue distribution of fibroblast growth factor-1 after intra-arterial delivery. ASAIO Journal 41:M630-M633, 1995.

Kang SS, Gosselin C, Ren D, Greisler HP. Selective stimulation of endothelial cell proliferation with inhibition of smooth muscle cell proliferation by FGF-1 plus heparin delivered from fibrin glue suspensions. Surgery 118:280-287, 1995.

Gosselin C, Ren D. Ellinger J, Greisler HP. In vivo platelet deposition on polytetrafluoroethylene coated with fibrin glue containing fibroblast growth factor-1 and heparin in a canine model. Am J Surg 170:126-130, 1995.

Greisler HP. The role of monocytes/macrophages in the formation of intimal hyperplasia. In: Intimal Hyperplasia. Dobrin PB (Ed.), RG Landes Publishing, Austin, TX, pp 193-210, 1994.

Greisler HP, Cziperle DJ, Petsikas D, Murchan PM, Appelgren EO, Drohan W, Burgess WH, et al. Enhanced endothelialization of expanded PTFE grafts by heparin binding growth factor-type I (HBGF-1) pretreatment. Surgery 112:244-255, 1992.

Lam TM, Whereatt NE, Henderson SC, Greisler HP. Effects of hypercholesterolemia on monokines-induced smooth muscle proliferation. In: Angiogenesis-Key Principles-Science-Technology-Medicine. Steiner E, Weisz PB, Langer R. (Eds.), Birkhauser Verlag Basel, Switzerland, pp 346-356, 1992.

Greisler HP. New biologic and synthetic vascular prosthesis. RG Landes Company, Austin, TX, 1991.

Projects Completed or Active (Selected)

• Evaluation of Newer Vascular Prostheses
• Growth Factor Mediation of Healing of Vascular Grafts
• HBGF-1/Fibrin Glue - 30cm Implants
• FGF-Saporin Mitotoxin to Inhibit Myointimal Hyperplasia
• Antisense Oligonucleotide Inhibition of Myointimal Hyperplasia
• Retention of t-PA Transfected Endothelial Cells on Fibrin Glue Coated Vascular Grafts in vitro
• Novel Bicomponent Fiber Technologies for Bioresorbable Vascular Grafts
• FGF-1 Supplemented Fibrin Glue-Cardiovascular Graft Program

Research Funding Sources

• American Red Cross
• C.R. Bard Cardiovascular
• Ethicon, Inc.
• Loyola University Medical Center
• Monsanto
• National Institutes of Health
• PRIZM Pharmaceuticals
• Texas Biotechnology Corporation

Research Methods Employed

• Cell Culture, Growth Assays
• Coagulation Studies, Platelet Function
• Contractility
• DNA Assays
• RIA, ELISA
• Surgery, Histology

Honors

• 1996 - President-elect, Midwestern Vascular Surgical Society
• 1991-1995 - Member - NIH Surgery and Bioengineering Study Section
• 1982 - Vascular Surgery Research Award - Liebig Foundation (North America)